A Phase II Study of Cyclophosphamide Followed by Topotecan in Patients With Refractory or Relapsed Acute Myelogenous Leukemia
OBJECTIVES: I. Evaluate the efficacy of cyclophosphamide followed by topotecan in patients
with relapsed or refractory acute myelogenous leukemia. II. Confirm safety and tolerability
of this combination on this schedule in these patients.
OUTLINE: Patients receive cyclophosphamide intravenously over 1 hour on day 1 followed by
topotecan as a continuous 120 hour infusion starting 12 hours after completion of
cyclophosphamide. Treatment may be repeated every 3-6 weeks for at least 2 courses.
PROJECTED ACCRUAL: A total of 26 patients will be accrued for this study.
Primary Purpose: Treatment
Carole Miller, MD
Sidney Kimmel Comprehensive Cancer Center
United States: Federal Government
|Johns Hopkins Oncology Center||Baltimore, Maryland 21287|